click to watch our newest corporate video
Our vision is to empower humanity with a healthier future through transformative science. Our mission is to leverage the Trimer-Tag™ technology platform and our manufacturing capabilities for the discovery, development and commercialization of novel vaccines and biologic therapies.
With our leading COVID-19 vaccine candidate SCB-2019 (CpG 1018/Alum), we expect to commercialize one of the first protein-based COVID-19 vaccines enabling us to potentially help address the global shortage of COVID-19 vaccines.
The Trimer-Tag™ technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets.
We have built our product pipeline by employing the Trimer-Tag™ technology platform.
Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines
Clover Provides Update on 2022 Corporate Milestones
Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate
